On January 12, 2026, Zymeworks expanded and refreshed its executive bench and Board to align with the corporate strategy unveiled in November 2025. Investment veteran Brian Cherry joined the Board, bringing over 25 years of private equity experience and having overseen investments totaling more than $25 billion in enterprise value. The Board was streamlined from twelve to nine members over the past year, enhancing focus on capital allocation and strategic acquisitions. Internally, Mark Hollywood was elevated to Executive Vice President and Chief Operating Officer, while Dr. Sabeen Mekan transitions to Chief Medical Officer on February 1, 2026. Five senior finance, development and communications leaders were also appointed or promoted, and a search is underway for a permanent Chief Financial Officer. These moves underscore Zymeworks’ commitment to strengthen clinical, operational and financial leadership in preparation for the next phase of growth.

At the ASCO-GI conference, Zymeworks reported that the HERIZON-GEA-01 trial met its co-primary endpoints, demonstrating over two years median overall survival in first-line HER2-positive gastroesophageal adenocarcinoma with zanidatamab plus chemotherapy. The study showed a statistically significant improvement in progression-free survival versus trastuzumab regimens and consistent efficacy across PD-L1 subgroups, with a manageable safety profile. Upon regulatory approvals in the United States, Europe, Japan and China, Zymeworks stands to receive up to $440 million in milestone payments. These potential payouts substantially exceed the company’s most recent quarterly revenues of $27.6 million, underpinning a transformational cash-flow opportunity as Ziihera advances toward global launch.

Building on 2025 achievements—including three new Board additions, over $69.6 million in milestone receipts from partners and completion of $60 million in share repurchases—Zymeworks outlined a 2026 roadmap focused on integrating royalty growth, targeted acquisitions and disciplined internal R&D. The company ended 2025 with approximately $270.6 million in cash and marketable securities, projected to fund operations through 2028 when combined with anticipated milestones. Zymeworks plans to continue Phase 1 clinical development of its antibody-drug conjugate candidates ZW191 and ZW251, initiate the first clinical study for its IL-4Rα x IL-33 bispecific program (ZW1528), and leverage partnerships to advance additional ADCs. This integrated model aims to deliver predictable cash flows from licensed products while fueling innovation in high-value therapeutic assets.